Selective KRAS G12D inhibitors show early activity in advanced cancers
Selective KRAS G12D inhibitors showed encouraging activity in advanced cancers with G12D mutations across two early clinical studies, according to a commentary in Nature Medicine. The findings signal a transformative change for RAS-driven cancers. The commentary said the inhibitors could have potential applications across multiple tumor types and stages of disease. The underlying research by Riedl, J. M. et al. appeared in Cancer Cell, volume 44, pages 471 to 497 in 2026.
Advanced cancers carrying the KRAS G12D mutation may soon have new targeted treatments, across several tumor types, if early results hold up.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].